

Mark R Toshner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4296351/mark-r-toshner-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109
papers

7,830
citations

40
h-index

88
g-index

128
ext. papers

12,561
ext. citations

12.4
avg, IF

5.11
L-index

#	Paper	IF	Citations
109	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity.. <i>Nature</i> , 2022 ,	50.4	95
108	The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension.. <i>Chronic Respiratory Disease</i> , 2022 , 19, 14799731221078473	3	0
107	Coagulation Factor V is a T cell inhibitor expressed by leukocytes in COVID-19.. <i>IScience</i> , 2022 , 103971	6.1	1
106	The impact of hypoxia on B cells in COVID-19.. <i>EBioMedicine</i> , 2022 , 77, 103878	8.8	3
105	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. <i>Nature Communications</i> , 2021 , 12, 7104	17.4	1
104	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1275-1287	35.1	58
103	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021 , 397, 881-891	40	495
102	A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021 , 11, 2045894021995055	2.7	0
101	Single-cell multi-omics analysis of the immune response in COVID-19. <i>Nature Medicine</i> , 2021 , 27, 904-916	50.5	101
100	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1351-1362	40	316
99	Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. <i>ELife</i> , 2021 , 10,	8.9	40
98	Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom. <i>Clinical Trials</i> , 2021 , 18, 615-621	2.2	0
97	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021 , 596, 417-424	52.4	163
96	Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. <i>Immunity</i> , 2021 , 54, 1257-1275.e8	32.3	52
95	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	9
94	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	9
93	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021 , 397, 99-111	40	2110

92	Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. <i>Cardiovascular Research</i> , 2021 , 117, 2309-2325	9.9	10
91	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 605-612	40	117
90	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 1301-1326	5.8	3
89	Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH. <i>European Respiratory Journal</i> , 2021 ,	13.6	6
88	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021 , 13, eabj7211	17.5	20
87	Vascular Thrombosis in Severe Coronavirus Disease 2019 Requiring Extracorporeal Membrane Oxygenation: A Multicenter Study. <i>Critical Care Medicine</i> , 2021 ,	1.4	1
86	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021 , 599, 114-119	50.4	334
85	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021 , 398, 981-990	40	68
84	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. <i>Pulmonary Circulation</i> , 2021 , 11, 20458940211052823	2.7	1
83	Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 1223-1234	5.8	5
82	Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients: A Self-Controlled Case Series Analysis of a Nationwide Cohort. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2587-2597	6.4	9
81	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 586-594	10.2	14
80	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. <i>Nature</i> , 2020 , 583, 90-95	50.4	69
79	CAMPOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	8
78	Whole-genome sequencing of patients with rare diseases in a national health system. <i>Nature</i> , 2020 , 583, 96-102	50.4	139
77	Response to letter to the Editor: Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 756-757	15.4	1
76	Response to: Direct oral anticoagulants: Still too early for prime time after pulmonary endarterectomy?. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 759-761	15.4	
75	CASPA (CArdiac Sarcoidosis in PAPworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study. <i>BMJ Open Respiratory Research</i> , 2020 , 7,	5.6	2

74	Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. <i>ELife</i> , 2020 , 9,	8.9	302
73	Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19. <i>ELife</i> , 2020 , 9,	8.9	31
72	Characterization of Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 575-585	10.2	46
71	A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 114-122	15.4	45
70	Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. <i>Cell Reports Medicine</i> , 2020 , 1, 100062	18	37
69	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. <i>Cell Reports Medicine</i> , 2020 , 1, 100099	18	40
68	Repurposing of medications for pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020941494	27	14
67	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. <i>BMJ Open</i> , 2020 , 10, e044566	3	4
66	Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2020 ,	5.2	9
65	Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience. <i>Open Heart</i> , 2020 , 7, e001144	3	29
64	Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	1
63	The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	16
62	Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia. <i>American Journal of Human Genetics</i> , 2019 , 104, 948-956	11	17
61	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	17
60	Arrhythmic Burden and Outcomes in Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2019 , 6, 169	4.9	5
59	Chronic thromboembolic pulmonary hypertension following long-term peripherally inserted central venous catheter use. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894019859474	2.7	2
58	Tricuspid regurgitation and the right ventricle in risk stratification and timing of intervention. <i>Echo Research and Practice</i> , 2019 , 6, R25-R39	2	17
57	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 227-238	35.1	55

56	Myeloid angiogenic cells exhibit impaired migration, reduced expression of endothelial markers, and increased apoptosis in idiopathic pulmonary arterial hypertension. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019 , 97, 306-312	2.4	3
55	Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	10
54	BMP9 Morphs into a Potential Player in Portopulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 819-821	10.2	4
53	The outcome of reoperative pulmonary endarterectomy surgery. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018 , 26, 932-937	1.8	7
52	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , 2018 , 9, 1416	17.4	182
51	Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018 , 8, 2045893217735820	2.7	49
50	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. <i>American Journal of Human Genetics</i> , 2018 , 103, 3-18	11	27
49	Increased Antielastase Activity in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018 , 59, 652-655	5.7	0
48	Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e002087	5.2	33
47	Hematopoietic stem cell transplantation alters susceptibility to pulmonary hypertension in Bmpr2-deficient mice. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018801642	2.7	5
46	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. <i>American Journal of Human Genetics</i> , 2018 , 103, 144-153	11	18
45	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. <i>American Journal of Human Genetics</i> , 2017 , 100, 334-342	11	14
44	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. <i>American Journal of Human Genetics</i> , 2017 , 100, 75-90	11	235
43	Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017 , 136, 2022-2033	16.7	75
42	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. <i>Thorax</i> , 2017 , 72, 1035-1045	7.3	20
41	The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	3
40	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017 , 135, 460-475	16.7	96
39	Age should not be a barrier for pulmonary endarterectomy in carefully selected patients. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	3

38	Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 2078-87	9.4	83
37	The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities. <i>Thorax</i> , 2016 , 71, 462-73	7.3	94
36	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. <i>Circulation</i> , 2016 , 133, 1761-71	16.7	203
35	HIF2 β arginase axis is essential for the development of pulmonary hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 8801-6	11.5	97
34	Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1355-65	10.2	19
33	Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood. <i>Journal of Visualized Experiments</i> , 2015 , e53384	1.6	34
32	Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 859-72	10.2	89
31	The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease. <i>Physiological Reports</i> , 2015 , 3, e12363	2.6	19
30	Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. <i>Life Sciences</i> , 2014 , 118, 391-6	6.8	12
29	Transcript analysis reveals a specific HOX signature associated with positional identity of human endothelial cells. <i>PLoS ONE</i> , 2014 , 9, e91334	3.7	37
28	Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. <i>European Respiratory Journal</i> , 2014 , 44, 1635-45	13.6	140
27	Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment. <i>F1000prime Reports</i> , 2014 , 6, 38		12
26	Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013 , 305, H259-64	5.2	64
25	Reply to "Letter to the editor: Pulsatile pulmonary artery pressure: are fluid-filled catheters accurate in pulmonary hypertension?". <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013 , 305, H1682	5.2	1
24	The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. <i>Human Molecular Genetics</i> , 2013 , 22, 3667-79	5.6	77
23	A practical and efficient cellular substrate for the generation of induced pluripotent stem cells from adults: blood-derived endothelial progenitor cells. <i>Stem Cells Translational Medicine</i> , 2012 , 1, 855-65	6.9	44
22	Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. <i>Circulation</i> , 2012 , 126, 1099-109	16.7	68
21	Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH. <i>European Respiratory Journal</i> , 2012 , 40, 612-7	13.6	31

20	Risk of potentially life-threatening thyroid dysfunction due to amiodarone in idiopathic pulmonary arterial hypertension patients. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 997-8	15.1	5
19	Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2011 , 1, 244-9	2.7	10
18	Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. <i>Thorax</i> , 2011 , 66, 326-32	7.3	65
17	Endothelial progenitor cells in pulmonary hypertension - dawn of cell-based therapy?. <i>International Journal of Clinical Practice</i> , 2010 , 64, 7-12	2.9	13
16	Pulmonary hypertension: advances in pathogenesis and treatment. <i>British Medical Bulletin</i> , 2010 , 94, 21-32	5.4	16
15	Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 1171-7	10.2	276
14	Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 610-5	5.8	15
13	Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 780-7	10.2	171
12	Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2008 , 31, 736-41	13.6	64
11	Current differences in referral patterns for pulmonary endarterectomy in the UK. <i>European Respiratory Journal</i> , 2008 , 32, 660-3	13.6	3
10	NT-proBNP does not rise on acute ascent to high altitude. <i>High Altitude Medicine and Biology</i> , 2008 , 9, 307-10	1.9	17
9	Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. <i>Chest</i> , 2008 , 134, 229-236	5.3	192
8	Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). <i>Vascular Pharmacology</i> , 2007 , 46, 449-55	5.9	28
7	Treatment options in pulmonary arterial hypertension. <i>Future Prescriber</i> , 2007 , 8, 5-8		
6	Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. <i>Thorax</i> , 2007 , 62, 617-22	7.3	26
5	Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. <i>Respiratory Medicine</i> , 2007 , 101, 2254-62	4.6	42
4	Bayesian inference associates rare KDR variants with specific phenotypes in pulmonary arterial hypertension		3
3	Physical, cognitive and mental health impacts of COVID-19 following hospitalisation in a multi-centre prospective cohort study		17

2	Factor V is an immune inhibitor that is expressed at increased levels in leukocytes of patients with severe Covid-19	1
1	Delayed bystander CD8 T cell activation, early immune pathology and persistent dysregulation characterise severe COVID-19	4